Esas cifras proceden de estudios con poblaciones, duraciones, criterios de inclusin y variables de anlisis diferentes, y no son comparables entre s
Halminen J, Sattaer N, Rawshani A et al (2022) Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes
Canada added the cardiovascular label in 2024, and provincial formularies followed by mid-2025, expanding patient eligibility
Semaglutide mimics the GLP-1 hormone, which can reduce appetite, slow stomach emptying, and help you feel satisfied with smaller portions when paired with healthy habits